Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis

Código QR

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis

Handan Canan,1 Selçuk Sizmaz,2 Rana Altan-Yaycioğlu,1 Çağla Saritürk,3 Gürsel Yilmaz41Department of Ophthalmology, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 2Department of Ophthalmology, Çukurova University S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Canan H, Sızmaz S, Altan-Yaycıoğlu R, Sarıtürk C, Yılmaz G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	age-related macular degeneration (AMD) optical coherence tomography (OCT) ranibizumab visual acuity Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/982ea80c5aa34d329b31270e8bf84050
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar P, et al.
Publicado: (2021)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Maria Cristina Savastano, et al.
Publicado: (2021)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi H, et al.
Publicado: (2018)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
por: Karagiannis D, et al.
Publicado: (2017)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
por: Michalska-Małecka K, et al.
Publicado: (2016)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto S, et al.
Publicado: (2018)

Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections
por: Strzalka-Mrozik B, et al.
Publicado: (2017)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
por: Asahi MG, et al.
Publicado: (2020)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

Early and intermediate age-related macular degeneration: update and clinical review
por: García-Layana A, et al.
Publicado: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken E, et al.
Publicado: (2020)

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
por: Arias L, et al.
Publicado: (2016)

Differential Circulating MicroRNA Expression in Age-Related Macular Degeneration
por: Hanan ElShelmani, et al.
Publicado: (2021)

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi Y, et al.
Publicado: (2017)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020)

The effect of intravitreal injections on dry eye, and proposed management strategies
por: Laude A, et al.
Publicado: (2017)

Vitrectomy in patients 85 years of age and older: surgical outcomes and visual prognosis
por: Anteby R, et al.
Publicado: (2018)

The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano M, et al.
Publicado: (2016)